register

News & Trends - MedTech & Diagnostics

Surgeons slam Private Healthcare Australia for allegedly manipulating public perception of device reps

Health Industry Hub | April 22, 2024 |

MedTech & Diagnostics News: Private Healthcare Australia (PHA) faces severe backlash over its alleged attempts to steer public perception regarding rising costs in the private healthcare system. The latest uproar stems from a news story which portrays medical device representatives as mere “sales reps” who have “infiltrated operating theatres without patient consent.”

The story featured Professor Kerin Fielding, President of the Royal Australasian College of Surgeons (RACS), defending the presence of medical device theatre reps are indispensable members of the surgical team, possessing advanced knowledge of cutting-edge technology crucial for safe and efficient procedures.

Melbourne-based orthopaedic surgeon, Dr Claudia Di Bella, condemned the piece as biased, asserting that it unfairly amplifies the views of private health insurers.

“This is so biased it makes me sick! The views of private health insurers boosted while the opinion of RACS President just skimmed. Insurers do not cover patients for the cost of their medical care, they merely pay for hospital and implants. Now they want to reduce their expenses on that and still make doctors/surgeons look like we are the bad guys. We need product reps because we want to be able to use the necessary implants in the best way. We are not stupid, brainless people who just fall for the first salesman!” Dr Di Bella stressed.

Dr Nigel Hartnett, a knee and orthopaedic surgeon, vehemently rejected the notion that theatre reps are solely motivated by sales agendas.

“Theatre reps are not in my theatre to sell products, they are not in my theatre to upsell anything and if they were they would be booted out. Theatre reps are indispensable, they provide an excellent knowledge base for not only myself but my scrub team particularly in complex cases. Theatre reps are an integral part of the team and I tell my patients that there will be a theatre rep to provide expertise and help during the case,” he asserted.

Dr Ilan Freedman, an orthopaedic surgeon specialising in hip and knee procedures, echoed similar sentiments, labelling the article as “outrageous”.

“My reps are indispensable to optimised patient care. Theatre nurses deal with multiple different implants and the number of instruments would be in the 100s. The reps support the theatre team, and are also instrumental in planning and efficient execution of my cases.”

The controversy surrounding PHA’s alleged manipulation of the narrative underscores deep-seated tensions within the private healthcare sector, with stakeholders clashing over issues of cost, quality, and optimal patient care.

The Australian Medical Association (AMA) and Catholic Health Australia (CHA) have recently criticised insurers for falling short of the widely acknowledged benchmark of returning 90% of premiums to their members while spending big on salaries, bonuses, advertising and sponsorships.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Roche's immunotherapy drug shows promising results for Australian patients with rare blood cancer

Roche’s immunotherapy drug shows promising results for Australian patients with rare blood cancer

Health Industry Hub | October 8, 2024 |

Pharma News: Roche’s immunotherapy drug has shown high response rates in patients with a rare form of blood cancer that […]

More


News & Trends - Pharmaceuticals

Government seals deal with industry for rare cancer therapy

Government seals deal with industry for rare cancer therapy

Health Industry Hub | October 8, 2024 |

Pharma News: Australian children and young adults diagnosed with high-risk neuroblastoma will continue to receive free access to a promising, […]

More


News & Trends - MedTech & Diagnostics

Abbott showcases leadless pacemaker system to local stakeholders

Abbott showcases leadless pacemaker system to local stakeholders

Health Industry Hub | October 8, 2024 |

MedTech & Diagnostics News: Leadless pacemakers are promising alternatives to transvenous pacing. Abbott hosted a stakeholder event at the recent […]

More


News & Trends - Pharmaceuticals

Australian scientists pivotal in new drug class from BMS

Australian scientists pivotal in new drug class from BMS

Health Industry Hub | October 8, 2024 |

Pharma News: The first new class of drug for schizophrenia in decades has been approved, offering a fresh approach by […]

More


This content is copyright protected. Please subscribe to gain access.